Printer Friendly

COURT APPROVES $3.8 MILLION SETTLEMENT IN GENERIC DRUG CLASS ACTION SUIT

COURT APPROVES $3.8 MILLION SETTLEMENT IN GENERIC DRUG CLASS ACTION SUIT
 PHILADELPHIA, Nov. 11 /PRNewswire/ -- A federal judge has approved a $3.8 million settlement agreement in a class-action lawsuit against generic drug manufacturer Bolar Pharmaceutical Company (AMEX: BLR), it was announced today by the Philadelphia law firm of Kohn, Klein, Nast & Graf, P.C.
 Purchasers of Bolar's generic versions of Dyazide -- a widely prescribed high blood pressure medication -- or Macrodantin -- an antibiotic used to treat urinary tract infections -- may be eligible to receive payments from the settlement fund if they submit valid claim forms. Eligible participants will receive either the amount they paid for the Bolar drugs, or a pro-rated share of their claims.
 Federal Judge Edward N. Cahn approved the settlement of the lawsuit filed by consumers who had bought the drugs. The case consolidated several class-action suits filed against Bolar in 1990, said Dianne Nast of Kohn, Klein, Nast & Graf, lead attorney for the plaintiff class. Nast is a nationally known class action attorney.
 The lawsuit alleged that Bolar had knowingly falsified documents filed with the U.S. Food and Drug Administration when it submitted the generic drugs for approval. Under the terms of the settlement, Bolar admitted no wrongdoing but agreed to establish the fund to settle the lawsuit.
 To participate in the settlement, a consumer must have purchased the drugs between Aug. 21, 1987, and Dec. 12, 1990, in the United States, its territories or possessions. To obtain a claim form, written requests must be sent to Bolar Pharmaceutical Litigation, P.O. Box 57, Philadelphia, Pa., 19105. Completed forms must be postmarked no later than Feb. 28, 1992.
 /delval/
 -0- 11/11/91
 /CONTACT: Dianne Nast or Douglas Abrahams, 215-238-1700, both of Kohn, Klein, Nast & Graf/
 (BLR) CO: Bolar Pharmaceutical Company; Kohn, Klein, Nast & Graf, P.C. ST: New York, Pennsylvania IN: MTC SU: KA-JS -- PH008 -- 3021 11/11/91 12:04 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 11, 1991
Words:319
Previous Article:CASPEN OIL REPORTS FINANCIALS FOR THE YEAR ENDED JULY 31, 1991
Next Article:AIRPORTS COMMISSION, NORTHWEST AIRLINES NEGOTIATORS REACH AGREEMENT ON TERMS OF LOAN TO NORTHWEST
Topics:


Related Articles
CLASS-ACTION SUIT PRESCRIBES RELIEF FOR MEDICAL CONSUMERS
DEADLINE ISSUED FOR BOLAR PHARMACEUTICAL CLAIMS
CLASS ACTION PETITION HEARING SET FOR SEPT. 16 IN DETROIT: TARGETS GENERIC PHARMACEUTICAL MAKER FOR PRODUCING FRAUDULENT, UNSAFE DRUGS
/ C O R R E C T I O N -- CLASS ACTION PETITION HEARING /
FEDERAL JUDGE GRANTS CLASS ACTION PETITION AGAINST GENERIC DRUG MAKER
Andrx-Hoechst Sued in Michigan Class Action by Cardizem CD Users Charging Price Fixing and Conspiracy to Keep Generic Competitors Off Market
Consumer class actions follow suits by generic drug makers against brand-name companies.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters